GlassScriptPhysician profile
Chase L Vervack
NPI 1285947895
$5,313.14
in general payments reported to CMS, 2019-2025
11 companies · $270 in 2025
The $270 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $579 · 2020: $235 · 2021: $1,007 · 2022: $1,475 · 2023: $1,047 · 2024: $700 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,017.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,017.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,875.75 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $1,071.39 | 2019-2025 | Total30, Precision7, Precision 7 |
| Coopervision INC. | $643.83 | 2020-2025 | Myday Contact Lens, Biofinity Contact Lens, Clariti Contact Lens |
| Glaukos Corporation | $401.51 | 2021-2022 | |
| Rxsight INC | $287.45 | 2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Allergan, INC. | $236.50 | 2019-2022 | |
| New World Medical,INC. | $233.02 | 2023 | |
| Dompe US, INC. | $224.55 | 2021-2022 | |
| The Cameron-Ehlen Group, INC. | $162.50 | 2021 | |
| Abbvie INC. | $110.68 | 2023 | Vuity |
| Shire North American Group INC | $65.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chase Vervack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.